- Original article
- Open Access
Scope on idiopathic pulmonary fibrosis in Upper Egypt
Egyptian Journal of Bronchology volume 9, pages 154–159 (2015)
Clinical features of idiopathic pulmonary fibrosis (IPF) are not the same in all patients and are characterized by being nonspecific. Symptoms range from nothing at all to severe disabling dyspnea.
To explore the demographic, clinical and physiological characteristics of IPF patients attending the outpatient clinic at El-Minia and Assiut University Hospitals to see whether they match with or differ from the common features of the disease known worldwide.
Patients and methods
One hundred-twenty six patients diagnosed as IPF underwent detailed history taking, clinical examination, spirometery, oxygen saturation and trans-thoracic echocardiography.
About 43% of patients developed IPF before age of 50 and the mean age at time of diagnosis was 48.6 ± 12.9 years. Eighty four (66.7%) patients were males. Ninety (71.4%) patients had significant tobacco smoke exposure. Dyspnea was present in 120 (95.2%) patients and the majority had grade 3 and 4 dyspnea. Ninety-five percentage of patients had cough. Clubbing of fingers was present in 72 (57.1%). All patients had bilateral basal crepitation. The mean of FVC was 52.5 ± 15.2% while the mean O2 saturation was 91.9 ± 4.8%. One third of patients (33.3%) had corpulmonal and those have significantly longer duration of illness and significantly lower FVC and O2 saturation (P < 0.001 for each).
In our locality IPF patients had younger age of presentation while other demographic, clinical and physiological features were more or less similar to those recorded worldwide.
American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. Am J Respir Crit Care Med 2000; 161: 646–664.
American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277–304.
Visscher DW, Myers JL. Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 322–329.
Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980–985.
Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27:136–142.
Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810–816.
Nadrous HF, Myers JL, Decker PA, Ryu JH. Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clin Proc 2005; 80:37–40.
Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 285–292.
Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132:998–1006.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788–824.
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581–586.
Carroll DG Jr. Curvature of the nails, clubbing of the fingers and hypertrophic pulmonary osteoarthropathy. Trans Am Clin Climatol Assoc 1972; 83:198–208.
Gnecchi-Ruscone T, Rigo F. Normal range for pulmonary artery systolic pressure. JAMA 2008; 299:2022–2023.
Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967–972.
Costabel U, King TE. International consensus statement on idiopathic pulmonary fibrosis. Eur Respir J 2001; 17:163–167.
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 2000; 161: 646–664.
Garcia-Sancho Figueroa MC, Carrillo G, Pérez-Padilla R, Fernández-Plata MR, Buendía-Roldán I, Vargas MH, Selman M. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case–control study. Respir Med 2010; 104: 305–309.
Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161(Pt 1):1172–1178.
Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case–control study of environmental exposure to dust. BMJ 1990; 301:1015–1017.
Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 1994; 150: 670–675.
Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996; 347: 284–289.
Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006; 3:293–298.
Verma S, Slutsky AS. Idiopathic pulmonary fibrosis — new insights. N Engl J Med 2007; 356:1370–1372.
Kanematsu T, Kitaichi M, Nishimura K, Nagai S, Izumi T. Clubbing of the fingers and smooth-muscle proliferation in fibrotic changes in the lung in patients with idiopathic pulmonary.
Schwarz M, King TE, Cherniack RM. General principles and diagnostic approach to the interstitial lung diseases. In: Murray JF, Nadel JA, editors. Textbook of respiratory medicine. 2nd ed. Philadelphia: WB Saunders; 1994. 1803–1814.
Cottin V. Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey. Eur Respir Rev 2014; 23: 225–230.
Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J 2011; 37:743–746.
Spyros A, Zoe D, Malagarib K, Giorgos E, Sotiropouloua C, Milic-Emilic J, Roussosa C. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005; 99:755–761.
Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538–542.
Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med 2010; 123:304–311.
Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:1390–1394.
Sweet MP, Patti MG, Leard LE, Golden JA, Hays SR, Hoopes C, Theodore PR. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg 2007; 133:1078–1084.
Xaubet A, Agustí C, Luburich P, Roca J, Montón C, Ayuso MC, et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 431–436.
Nishiyamaa O, Taniguchia H, Kondoha Y, Kimuraa T, Ogawab T, Watanabeb T, Nishimurac K. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med 2005; 99:4408–4414.
Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, et al. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest 2005; 128(Suppl):616S–617S.
Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11: 452–455.
Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 2007; 82: 342–350.
Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129:746–752.
Nathan SD, Shlobin OA, Ahmad S, Koch J, Barnett SD, Ad N, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76: 288–294.
About this article
Cite this article
Rifaat, N., Hasan, A.A. Scope on idiopathic pulmonary fibrosis in Upper Egypt. Egypt J Bronchol 9, 154–159 (2015). https://doi.org/10.4103/1687-8426.158053
- cor pulmonale
- idiopathic pulmonary fibrosis